Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of Bolivian Mucosal Leishmaniasis
NCT04799236Phase 3Recruiting
- Sponsor
- Fundación Nacional de Dermatología
- Start
- Apr 2021
- Primary completion
- Apr 2024
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of liposomal amphotericin b in mucosal leishmaniasis (ML), sponsored by Fundación Nacional de Dermatología. Started Apr 2021; status: recruiting.
02
Drugs
liposomal amphotericin b
03
Conditions
mucosal leishmaniasis (ML)
Beyond the preview
Go deeper on NCT04799236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04799236.